hgsi

What to Watch: July 16, 2012

what to watch, hgsi, gsk, hum, citigroup, humana, glaxosmithkline, human genome sciences, fnno, business, finance, trading, stock market, analysis, news

By FNNO Staff
fnnonline@gmail.com

What's In The News: April 25, 2012

wall street, wsj, gasoline, crude, reuters, facebook, fb, instagram, microsoft, nyse, msft, human genome sciences, hgsi, glaxosmithkline, gsk, bloomberg, wal-mart, wmt, mexico, united states, business, finance, investing, stock, news, trading, analysis, market

By FNNO Staff
fnnonline@gmail.com

InterMune may receive $60 per share takeover offer

acquisition, analysis, business, esbriet, financial news, glaxosmithkline, gsk, hgsi, human genome sciences, intermune, itmn, market, merger, stock, trading

Rumors are swirling that InterMune will receive a $60 per share takeover offer. Several major drug companies are looking at InterMune following the FDA approval of its lung disease drug Esbriet. Industry sources say GlaxoSmithKlin

By FNNO Staff
fnnonline@gmail.com

Health Care Sector Update: March 10th, 2011

antibody, arena, arna, benlysta, disease, drug, fda, health, healthcare, hgsi, human genome, lupus, medical, patent, patient, pharma, sciences, shares, sle, stock, therapy, trade, treatment

Health care shares are down in mid-day trading, but Human Genome Sciences (HGSI) bucks the trend, after getting a key approval from the U.S. Food and Drug Administration. the FDA approved BENLYSTA to treat adult patients with acti

By Stephanie Shyu
sshyu@fnno.com

Human Genome Sciences Opens Up 12% After FDA OKs Lupus Treatment

analysis, benlysta, business, financial, glaxosmithkline, gsk, hgsi, human genome sciences, lupus, market, news, stock, trading

Human Genome Sciences (HGSI) is up 11% at the open after it and GlaxoSmithKline (GSK) said the U.S. Food and Drug Administration (FDA) approved BENLYSTA, a drug used to treat adult patients with type of lupus who are receiving sta

By FNNO Staff
fnnonline@gmail.com

Morning Market Snapshot: March 10th, 2011

aig, analysis, business, financial, glaxosmithkline, gsk, hgsi, human genome sciences, lsi, market, netapp, news, ntap, rio, rio tinto, stock, trading

Good Morning. It's Thursday, March 10, 2011. At this hour, U.S. equity futures are down. Overseas, the Asian markets declined, while the European markets are lower. Rio Tinto (RIO) raises bid for Riversdale Mining to A$16.50

By FNNO Staff
fnnonline@gmail.com

Latest News from FNNO

Waddell & Reed Financial: The Losing Str...

Waddell & Reed Financial (NYSE:WDR) traded at a new 52-week low today of $36.50. So fa ...

Shares of Valhi Fall to a New 52-Week Lo...

Shares of Valhi (NYSE:VHI) traded at a new 52-week low today of $2.33. So far today ap ...

Tim Participacoes: New 52-Week Low Set T...

Tim Participacoes (NYSE:TSU) traded today at a new 52-week low of $11.01. This new low ...

Shares of TransAlta Have Fallen Below Pr...

TransAlta (NYSE:TAC) traded today at a new 52-week low of $4.63. So far today approxim ...

Boston Beer: The Losing Streak Continues...

Shares of Boston Beer (NYSE:SAM) traded at a new 52-week low today of $195.04. So far ...

Shares of Saia Fall Below Previous 52-We...

Saia (NASDAQ:SAIA) traded today at a new 52-week low of $35.45. Approximately 256,000 ...

Shares of PetroChina Fall to a New 52-We...

PetroChina (NYSE:PTR) traded today at a new 52-week low of $76.29. This new low was re ...

Omega Healthcare Investors: The Losing S...

Omega Healthcare Investors (NYSE:OHI) traded at a new 52-week low today of $32.66. App ...

Most Popular Video News